



Contents

List of Tables	i-iv
List of Figures	v-xi
Chapter 1 - Introduction	1 - 5
1.1 Introduction	1
1.2 Objectives of the present work	3
1.3 References	4
Chapter 2 - Literature Review	6 - 53
2.1 Cancer: Introduction	6
• The magnitude of problem	7
• Measuring new cancer cases	8
• Cancer survival	8
• Measuring cancer deaths	9
• Types of cancers	9
• Cancer treatment	10
2.2 Methods of treatment	11
• Chemotherapy: Historic background	11
• Solid tumors	13
• Cell cycle	14
2.3 Nanotechnology in cancer treatment	15
2.4 Development in Liposomal Drug Delivery	17
• Long-circulating liposomes	17
• Immuno-liposomes.	19
2.5 New ligands for targeting liposomes	19
• Antibody-mediated liposome targeting	19
• Folate-mediated liposome targeting	20
• Transferrin-mediated liposome targeting	21
• pH-sensitive liposomes	21
2.6 Mechanisms of intracellular delivery mediated by pH-sensitive liposomes	23
• Biophysical properties underlying the pH sensitivity of liposomes	23
• Binding and cell internalization	24
• Destabilization of liposomes at the endosomal level	25
2.7 Role of DOPE in pH sensitive liposomes	26
• DOPE liposomes and its mechanisms of cytosolic delivery	26
• DOPE in long-circulating pH-sensitive liposomes	29
2.8 Alternative strategies under acidic conditions to generate fusogenic liposomes	33
• The use of novel pH-sensitive lipids	34
• Synthetic fusogenic peptides/proteins with cationic liposomes	35
• pH-sensitive polymers with liposomes	37
2.9 Applications of long circulating pH-sensitive liposomes for the delivery of anticancer drugs and other therapeutic molecules	38
2.10 References.	42
Chapter 3 - Drug Profiles	54-67

3.1 Introduction - Paclitaxel	54
• Description	54
3.2 Pharmacology	56
• Antitumor activity	56
• Pharmacokinetics	56
• Adverse Effects/Uncommon Effects	57
• Drug Interaction	57
• Dose	57
• Precaution	58
• Metabolism	58
3.3 Marketed Product	59
3.4 Introduction - Irinotecan	60
• Description	60
3.5 Pharmacology	62
• Antitumor activity	62
• Pharmacokinetics	62
• Adverse Effects/Uncommon Effects	62
• Drug Interaction	63
• Dose	63
• Precaution	63
• Metabolism	64
3.6 Marketed Product	65
3.7 References	66
Chapter 4 - Analytical Methods	68-86
4.1 Introduction	68
4.2 Estimation of Paclitaxel	68
• Solutions	68
• Procedure for calibration plot	68
• Stability and selectivity	69
• Accuracy and Precision	69
• Estimation of Paclitaxel from liposomes	69
4.3 High Performance Liquid Chromatography	72
4.4 Estimation of Irinotecan Hydrochloride	74
• Solutions	74
• Procedure for calibration curve	74
• Stability and selectivity	75
• Accuracy and Precision	75
• Estimation of Irinotecan Hydrochloride from liposomes	75
4.5 Fluorimetric estimation of Irinotecan Hydrochloride in double distilled water and human serum and human plasma	79
• Instrumentation	79
• Preparation of calibration plot in double distilled water	79
• Construction of calibration plot in human serum and plasma	79
• Accuracy and Precision	80
4.6 Results and discussion	82

4.7 References	85
Chapter 5 - Preparation and Characterization of Liposomes	87-157
5.1 Preparation of liposomes	87-119
5.1.1 Introduction	87
5.1.2 Experimental	88
• Material	88
• Apparatus	88
5.1.3 Preparation of conventional liposomes of Paclitaxel	88
5.1.4 Preparation of pH sensitive, Serum stable, long circulating liposomes	92
5.1.5 Methods	92
5.1.6 Preparation of pH sensitive Paclitaxel Liposomes	92
• Freeze-drying of Liposomal formulation	94
• Electrolyte induced flocculation test	96
5.1.7 Preparation of conventional liposomes of Irinotecan Hydrochloride	97
5.1.8 Preparation of pH sensitive Irinotecan Hydrochloride Liposomes	100
• Electrolyte induced flocculation test	103
5.1.9 Results and Discussion	104
• For conventional liposomal preparation	104
• For Serum stable, long circulating, pH sensitive liposomal formulations	111
5.2 Characterization of pH sensitive liposomes	120-154
5.2.1 Characterization of pH sensitive Liposomes of Paclitaxel	120-132
• Particle size	120
• Zeta potential	120
• Entrapment efficiency of Paclitaxel in liposomes	121
• Solid-state analysis (DSC and XRD)	122-124
◦ Differential Scanning Calorimetry (DSC)	122
◦ X-ray Diffraction studies (XRD)	123
• Transmission Electron Microscopy (TEM)	124
• pH induced liposomal aggregation and serum stability	125
• <i>In-vitro</i> drug release study	126
• Stability Study	127
5.2.2 Characterization of pH sensitive Liposomes of Irinotecan	133-154
• Particle size	133
• Zeta potential	133
• Entrapment efficiency of Irinotecan in liposomes	134
• Solid-state analysis (DSC and XRD)	135-137
◦ Differential Scanning Calorimetry (DSC)	135
◦ X-ray Diffraction studies (XRD)	136
• Transmission Electron Microscopy (TEM)	137
• pH induced liposomal aggregation and serum stability	138
• <i>In-vitro</i> drug release study	139
• Stability Study	140
5.2.3 Results and Discussion	146
5.2.4 Conclusion	155

5.2.5 References	155
Chapter 6 - <i>In-vitro</i> Cell Line Studies	158-200
6.1 Introduction	158
• Cell culture	158
6.2 Cytotoxicity Assay (MTT assay)	159
6.3 Leighton Tube Assay	164
6.4 Confocal microscopy	169
6.5 Cell proliferation	169
6.6 Cell Motility	178
6.7 Cell Cycle analysis	187
o Flow cytometry (FACS analysis)	187
6.8 Results and Discussion	192-199
• Paclitaxel (PCL) and its liposomal formulations	192
• Irinotecan (IH) and its liposomal formulations	196
6.9 Conclusion	199
6.10 References	200
Chapter 7 - Radiolabeling of Liposomes	201-226
7.1 Introduction	201
• Chemistry of Technetium	203
• Reduction of $^{99m}\text{TcO}_4^-$	203
• Labeling with reduced Technetium.	204
• Hydrolysis of reduced Technetium and Tin.	204
7.2 Materials	204
7.3 Radiolabeling of liposomal formulations	205
• Labeling efficiency	205
• Stability study of ^{99m}Tc labeled complex	206
• DTPA and Cysteine challenge test	206
7.4 Optimization of radiolabeling of PCL and its liposomal formulations	206
7.5 Optimization of radiolabeling of Irinotecan and its liposomal formulation	214
7.6 Results and Discussion	221-224
• Radiolabeling of PCL and its liposomal formulations	221
• Radiolabeling of Irinotecan and its liposomal formulations	223
7.7 References	225
Chapter 8 - <i>In-vivo</i> Biodistribution and Scintigraphy Studies	227-246
8.1 Introduction	227
8.2 Experimental	227
• Selection of animals	227
• Tumor implantation	228
8.3 Blood kinetic studies	228
8.4 Biodistribution and tumor uptake studies	231
8.5 Gamma Scintigraphy Imaging	238
8.6 Data analysis	240
8.7 Results and Discussion	240
• Paclitaxel (PCL) and its liposomes	241
• Irinotecan (IH) and its liposomes	243

8.8 Conclusions	245
8.9 References	246
Chapter 9 - <i>In-vivo</i> Anti-metastatic Activity	247-260
9.1 Evaluation of antimetastatic activity of pH-sensitive liposomes of PCL and IH in C57BL/6 mice using B16F10 melanoma model.	247
Animals	247
Melanoma cells	247
9.2 Tail vein metastasis assay	248
9.3 Histology	252
9.4 Results and discussion	255-259
• <i>In-vivo</i> antimetastatic activity of Paclitaxel and its liposomal formulations	256
• <i>In-vivo</i> antimetastatic activity of Irinotecan and its liposomal formulations	258
9.5 Conclusion	259
9.6 References	260
Chapter 10 - Summary and Conclusions	261-275
List of publications and papers presented in conferences	276-277